8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 19, 2016

CAREDX, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36536	94-3316839
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification Number)

3260 Bayshore Boulevard

Brisbane, California 94005

(Address of principal executive offices)

(415) 287-2300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. Results of Operations and Financial Conditions

On April 14, 2016, CareDx, Inc. (the “Company”) announced in a press release that it would be holding a conference call on April 19, 2016 to discuss the Allenex AB acquisition and provide details on upcoming milestones and the combined company financial outlook. The full text of the script and the full presentation for the conference call are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively.

This information is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Script for conference call on April 19, 2016
99.2	Presentation made by the Company for the conference call on April 19, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CAREDX, INC.
Date: April 21, 2016
	By:	/s/ Charles Constanti
	Charles Constanti
	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Script for conference call on April 19, 2016
99.2	Presentation made by the Company for the conference call on April 19, 2016

EX-99.1

Exhibit 99.1

CareDx Allenex Acquisition Conference Call

Tuesday, April 19th, 2016

1:30 p.m. PT/ 9:30 p.m. CET

Operator

Good morning, and welcome to CareDx’s conference call to discuss the combination of CareDx with Allenex . My name is Jonathan and I’ll be your coordinator operator for the call today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this conference is being recorded today, April 19, 2016. I would now like to turn the conference over to Mark Klausner, Investor Relations. Please go ahead.

Mark Klausner

Thank you for participating in today’s call. Joining me are Peter Maag, President and Chief Executive Officer, Charles Constanti, Chief Financial Officer, Anders Karlsson, CEO of Allenex and Matt Meyer, Chief Business Officer of CareDx.

Last Week CareDx completed the tender offer for Allenex in Sweden and completed a PIPE transaction. The releases describing these transactions are currently available on the company’s website at www.caredx.com.

In addition, there is a presentation available for download on the company’s website that management will refer to during today’s presentation.

Page 1

Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical fact should be deemed to be forward-looking statements. All forward-looking statements, including, without limitation, our examination of historical operating trends and our future financial expectations, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please see our filings with the SEC.

CareDx disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of today’s live broadcast.

I will now turn the call over to Peter Maag. Peter?

Peter Maag

Thanks, Mark.

Good afternoon to those of you in the U.S. and good evening to those of you in Europe. Thank you all for joining us.

Page 2

As with all of our calls, we start with the focus on transplant patients. Last Friday, April 15th was National Blue and Green day, an effort to promote the success of organ, eye and tissue transplantation and the extreme need for registered donors. Waitlists for patients in need of transplantation continue to be very long – with organ availability being a key issue. In case you did not wear Green and Blue Colors – make sure you do so in 2017 to support transplantation.

We are excited to share the news that we have completed the acquisition of Allenex, a transplantation focused diagnostics company based in Sweden.

I will start the call with an overview of the CareDx strategy. Then, Anders Karlsson who has joined us here for the week in San Francisco will introduce to you the Allenex product portfolio. Then Charles Constanti, in his first call as CFO for CareDx will talk you through financial information. I will come back on and provide our outlook for 2016. And we then look forward to answer your questions.

Turning to slide 4 you will see the compelling strategic rationale for the Allenex acquisition that we have been discussing since we announced the transaction. I believe the diagnostics industry will continue to consolidate as regulatory and business forces make it increasingly difficult to be a small, single product company. With the combination with Allenex, we have built a platform for growth with a focus on leadership in Transplantation. With the clinical application of genomic information and the focus on a patient centric longitudinal view – we will make a significant contribution to a medical field with continued great unmet medical need.

By combining our leading products, expertise and infrastructure, we have increased our critical mass as a company and positioned ourselves as a leader across the pre—to-post transplant continuum. Transplantation is a global business, with great

Page 3

similarities across the geographies. With CareDx and Allenex we have 2 organizations that greatly complement each other with our focus in the US and Allenex’ strength being in Europe.

Our approach to technology is also complementary — together we apply and master the important technologies in the molecular diagnostics field that impact clinical decision making. Collectively, we have two platforms: we have a platform for continued innovation with our CLIA lab and also a platform for providing distributed diagnostics. We will utilize the strengths of both platforms in our partnerships with the roughly 500 key transplant centers around the world.

Turning to slide five, we see the transplant market uniquely fitted for a nimble and focused diagnostics company. The pre-transplant market opportunity is approximately $500M – while we see a 3 times larger opportunity in Post-transplant surveillance. In future calls, we will go into more detail on the transplant opportunity. Let me mention that we are glad to have Todd Whitson joining the company as Chief Commercial Officer. With his expertise in cfDNA and experience garnered at Ariosa/Roche, Todd will not only focus on the launch of AlloSure but also provide a strong focus on driving commercial excellence in our organization.

On slide six, we provide an overview of the 2 businesses and our thoughts on synergies. We have outlined before that given the complementarity of our 2 businesses in respect of geography and call points, we see little cost synergies in the combination, but rather we see revenue synergies by exchanging information on transplant centers. And then we see even greater synergies by focusing on providing longitudinal clinical data sets that allow clinicians to make better decisions and support their approach to comprehensive patient management initiatives.

Page 4

On slide seven you can see that CareDx now has 2 substantial core products – products that are leaders in their respective fields. Olerup SSP is a best in class PCR- based HLA typing kit and AlloMap is a gene-expression based Heart transplant surveillance lab testing service. These 2 commercial products, which are best-in-class in their respective fields will provide the baseline revenue to the organization. In the pipeline we have QType, a PCR-based testing solution that will allow for rapid HLA typing which is especially critical in cadaveric solid organ matching and AlloSure, a novel cfDNA test that we are developing to detect transplant organ injury. These 2 launch products will provide the future revenue growth to the organization.

On slide eight, you can see the geographic split of revenues and products, based on our estimates on 2015 sales. You can also see core product revenue with AlloMap and Olerup SSP are 90% of our business and revenues in the US continue to be the major focus area for the company.

Let me now introduce Anders Karlsson. Anders has agreed to join the combined organization and will oversee the international business operations of the company. We are happy to have him as we have a strong focus on expanding our business internationally.

Anders Karlsson

Thank you Peter.

Page 5

I am excited about the combination of CareDx and Allenex and the opportunities we see for the combined company. Allenex, together with CareDx, already offers a portfolio of core products, and will also launch new products in 2016

Turning to slide 10, Olerup SSP kits have been a market leading product for more than 20 yrs. The company was founded by Associate Professor Olle Olerup who pioneered this field. Allenex acquired Olerup SSP from Olle Olerup in 2008 with a plan to build a global company for transplantation diagnostics. As a result Olerup International was formed in mid 2009 and is today selling the products globally. The company is headquartered in Stockholm, Sweden and has sales offices located in Vienna, Austria, and in West Chester, PA in the US.

Since inception, the company has set the standard for products for HLA typing based on PCR sequence specific primers or SSP technology. Olerup products are widely known to have the most updated HLA typing kits. The SSP technology is used for typing of both solid organs (low resolution typing) as well as for stem cells (high resolution typing). The Olerup SSP products are still growing on the global market and are still taking share within select established markets. Current growth is driven by the conversion of customers from competitors and from geographical expansion.

On slide 11, you will find a brief overview of Olerup SSP HLA typing kits together with the interpretation software SCORE. The product line includes more than 350 SKUs or individual kits for HLA typing. The kits are regularly updated for new recognized alleles that are registered in the global official allele database that is released quarterly. Our product line today types for more than 14,000 currently known alleles and kits and software are updated with every newly produced batch. The product has a very strong footprint in Europe and is taking share within the US market. The SCORE software is provided as a tool to the customers to help with the interpretation of the test. It is well known and established in the market for more than 10 years.

Page 6

All transplantation labs today use the SSP technology for HLA typing, but the range of usage differs among customer based in the size of lab and throughput of patient samples. However, the main customer for Olerup SSP typing kits are the small to medium sized HLA labs who are using a larger share of SSP typing products compared with the larger size labs.

Since April 2011, Olerup SSP has had the global distribution rights for a more automated solution for HLA typing. We sell SBT Resolver including the interpretation software Assign SBT from Conexio Genomics, an Australian company, that was recently acquired by Illumina Inc. These products complement the Allenex product portfolio and have added synergies into our sales.

Slide 12 introduces our launch product for 2016 – the QTYPE product line. QTYPE is a new product for HLA typing that provides results in 1 hour instead for 3-4 hours. The test is performed on q-PCR instruments and will be available on multiple automated instrument platforms. We expect the QTYPE product will be faster than the other products today available on q-PCR technology and will also be based on hydrolyzed probes technology (TAQMAN) which will allow the product platform to meet also future needs for fast and accurate results with a good level of resolution for solid organ typing. The fast and “easy-to-use” technology with good resolution will also allow Allenex to capture customers using the real time (q-PCR) platform from other technologies such as sequence specific oligos or SSO. The product will be introduced in 2^nd half of 2016, and will be provided with new and easy to use interpretation software - SCORE 6. Sales will come from reagents and instruments. We also expect to add other tests for the transplantation labs on the q-PCR platform to provide fast and “easy-to-use” data collection.

Page 7

On slide 13 we share the global footprint of our new organization. Allenex currently sells direct in US, Germany, Austria, Benelux and in the Nordics. Other markets globally are covered by experienced and highly skilled distributors with a strong position within their local markets. Historically, about 50% of Allenex sales are via distributors and mainly within Europe and the US.

The combined company will have a strong presence in the US and Europe, but also cover most countries that perform solid organ and stem cell transplantation globally. The presence in key markets as well as partnerships with strong distributors affords us the opportunity to explore product launches and distribution agreements with future new partners. The current infrastructure gives the combined company a strong global presence with the transplantation diagnostic laboratories.

On slide 14, you see an overview of our current sequencing offering. As I mentioned earlier, Allenex/Olerup has the global distribution rights for SBT typing products from Conexio Genomics. We have seen a healthy growth of these products within the large transplantation labs, especially in the US market. Today, we have today approximately 1/3 of the labs in the US as our customers performing SBT. Conexio Genomics was acquired in January 2016 by Illumina who has a long-standing partnership with CareDx. We are assessing our future growth strategy within the sequencing market for transplantation diagnostics.

I am now happy to hand over to Charles Constanti, the new Chief Financial Officer at CareDx.

Page 8

Charles Constanti

Thanks, Anders. I am excited to be here at CareDx during this transformational time. Last week was significant with a number of strategic steps taken to build a pre-and post-transplant company with a significant international footprint. Slide 16 gives a snapshot of the combined company.

Allenex Acquisition Deal Terms

Slide 17 shows the breakdown of the purchase price for Allenex. The acquisition premium was between 20 and 25%. The acquisition closed on April 14, 2016 and the consideration was a mix of cash and stock that totals approximately $35.1 million. Cash was paid and shares were issued to settle tendered shares and we currently own 98.3% of the Allenex common stock. Procedures to acquire the remaining shares and delist Allenex from the NASDAQ exchange in Stockholm will begin shortly.

The cash paid was $13.6 million or 39% of the consideration and $7.2 million worth of, or approximately 1.4 million shares of common stock were issued, representing 21% of the consideration. $8 million was retained by us as a commitment to purchase equity and $6 million was deferred for subsequent payment, together representing 40% of the consideration.

PIPE Financing

Slide 18 describes the $22 million private placement we closed last week to support the Company’s acquisition and working capital needs. There are two parts of the transaction. The initial portion of the placement represented a gross $14.1 million of

Page 9

equity at $3.99 per share with 50% warrant coverage. There is also a commitment to purchase another gross $8 million of equity on the same terms as the placement closed last week. The equity purchase pursuant to this commitment is expected to close during the current 2^nd quarter.

The form of the placement was units consisting of common stock, mandatorily convertible preferred stock and warrants. Conversion of the preferred stock into common shares is expected to occur in June of this year following shareholder approval at our planned Annual Meeting. Voting agreements are in place that support the approval of the placement.

By the end of the current quarter we expect to have approximately 19 million shares outstanding, including closing the equity purchase commitment and conversion of the preferred following the Annual Meeting.

Debt Financing

Page 19 provides some additional detail on the structure of the PIPE transaction and also shows our combined debt profile which includes mostly bank debt with East West Bank in California and Danske Bank in Scandinavia, together with loans from former shareholder of Allenex that we assumed with the acquisition. In total, the debt is approximately $30 million at relatively low interest rates.

There was no loan from Oberland Capital.

As we think about cash usage going forward, the development of our two new product families, AlloSure and Q-type will use cash. There will also be costs associated with the integration of Allenex, particularly as it relates to the consolidation of international

Page 10

entities and meeting the accounting and internal control expectations for a public company in the US. There will also be cash used for the amortization or repayment of debt and obligations. We will evaluate alternatives for financing our operating needs.

I will turn the call back to Peter to wrap up and discuss our outlook and guidance for 2016.

Peter Maag

Thanks Charles.

On slide 21 you will see some of the key upcoming milestones that we will focus on this year. Toward the end of this month we will present Allosure data in heart at ISHLT in Washington. In June, we anticipate presenting Allosure data in kidney. And finally, in the second half of the year as Anders has discussed we will be launching QTYPE.

Guidance

Turning to guidance, in 2016 we expect revenue to grow by low to mid-single digits on a pro forma basis assuming that the acquisition closed at the beginning of 2016. This anticipates that meaningful revenue from our launch products will begin in 2017. Please note that the reported results will only include Allenex results subsequent to April 14^th, the date of acquisition.

Revenue and operating results for the first quarter of 2016 are expected to be flat with the fourth quarter of 2015, excluding the impact of financing and acquisition costs. The flat revenue result reflects a continued lag in collections as discussed previously on our year-end call. AlloMap Test volume increased approximately 10% in the first quarter of 2016 compared with the same period in 2015.

Page 11

With that, I would like to open the call to take your questions.

Peter Maag (after questions)

Thank you all for joining us today to discuss our acquisition of Allenex. We are really enthusiastic about the combination of our two companies and the ability to serve patients along the pre-to-post transplant continuum. We will look forward to speaking with you again on our first quarter operating results call in early May.

Page 12

EX-99.2

CareDx - Allenex Building a Comprehensive Global Transplant Diagnostics Leader Investor Conference Call April 19, 2016 ® Exhibit 99.2

Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding future financial position of CareDx, Inc. (“CareDx” or the “Company”), including financial targets, business strategy, and plans and objectives for future operations, are forward-looking statements. CareDx has based these forward-looking statements on its estimates and assumptions and its current expectations and projections about future events. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those that may be described in greater detail in a registration statement (including a prospectus) that the Company may subsequently file with the U.S. Securities and Exchange Commission (the “SEC”) for the transaction to which this communication relates. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. CareDx undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this presentation, to conform these statements to actual results or to changes in CareDx’s expectations. CareDx is an “emerging growth company” as defined under the Securities Act of 1933, as amended (the “Act”). These slides and the accompanying oral presentation are intended to qualify as communications permitted pursuant to Section 5(d) of the Act. The Company may file a registration statement (including a prospectus) under the Act with the SEC for the transaction to which this communication relates. In the event the Company conducts an offering, before you invest you should read the prospectus in the registration statement and other documents that the Company files with the SEC for more complete information about the Company and the offering. When available, you may obtain those documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Certain data in this presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company or the proposed offering. ®

Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A

Compelling Strategic Rationale Highly complementary technologies that address both pre/post transplant markets Combined annual revenue approximately $45M; Creates scale and additional growth opportunities Commercial scale and geographic diversification to support potential cross selling in EU and ROW Leadership in growing pre-to-post transplantation continuum; application of novel clinical diagnostics (NGS) ® Acquisition purchase price: ~$35M through a mix of cash and stock consideration Transaction expected to accelerate time to operating profitability Multi-product diversification with lab service and distributed diagnostics

Attractive Market Opportunity Post Transplant Pre Transplant Market Size: $500M Market1 $1.5B Market2 Focus: Organ Matching Rejection Monitoring Patient Eligibility Immune Suppression Dynamics: Donor Registries Novel Approach Fragmented labs Fragmented protocols Players: Thermo Fisher Immucor HistoGenetics Thermo Fisher Immucor Oxford Immunotec Analyst Reports, WECA Research and Stewart Han Consulting GODT and OPTN 2013 estimates on solid organ transplants. Stem cell procedure data estimates from WBMT.org website, company estimates ®

Creating a Pre-to-Post Transplant Continuum Longitudinal Data Reimbursement (Bundled Offering) Pre-Transplant Matching HLA Typing Kits; SSP, RT-PCR, SBT Lab Directors; HLA Labs in Tx Centers Direct Sales US/EU; distributors ROW Technology Portfolio Channel Access Synergies Post-Transplant Monitoring Post-Tx Surveillance CLIA lab; RT-PCR, NGS Direct Sales US Clinicians, Coordinators, Patients ® Surveillance Transplant Matching Longitudinal Clinical Data Comprehensive Patient Management

Transplant Product Portfolio ® Description: Automated SSP platform Pre-Dispensed PCR plates Hydrolysis probe technology All-in-one hot start PCR master mix Description: 115-120 different typing kits Covers ~6,000 different HLA alleles identified to date Low and high resolution typing offerings Fast accurate results with high resolution Core Products Description: Assess risk of heart transplant rejection FDA 510(k)-cleared Highly reproducible and quantitative 99% negative Predictive Value RT-PCR platform Description: Analytically validated clinical-grade next-generation sequencing (NGS) test Measures the percent of dd-cfDNA in solid organ transplant patients Quantifies dd-cfDNA in patients without prior knowledge of donor or recipient genotype Launch Products Post Transplant Pre Transplant

Serving the Global Transplant Market ® Total Revenues: ~$44M Sales by Geography: Sales by Product: Total Revenues: ~$44M Source: Allenex and CareDx 2015 Financial Reports

Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A

Introduction: Allenex/Olerup Innovation in Transplantation Diagnostics Olerup SSP AB pioneered the field of HLA typing in the early ’90s with the introduction of its invention: PCR-SSP (Sequence Specific Primer HLA typing) The invention by Assoc Prof Olle Olerup, founder and CEO of the company, quickly became the world standard and made transplantation labs swith to molecular typing techniques. Olerup SSP AB has since then continued to develop its product line and today the company has world recognition due to: Kit performance => quarterly updates for new alleles – ”best in class” Interpretation program Olerup SSP ScoreTM

Olerup SSP: Pioneer of SSP Technology for Rapid HLA typing ® Olerup SSP HLA Typing Kits Score 6 Interpretation Software Description: Approx. 350 different typing kits / SKU’s Covers ~14.000 different HLA alleles identified to date Both low and high resolution typing offerings Fast accurate results with a high level of resolution Commercial Impact: Allenex flagship product Strong base in small-to-medium sized hospital and reference labs

QTYPE: Comprehensive Automated Rapid HLA Typing QTYPE HLA Typing Kits Score 6 Interpretation Software Description: Automated SSP platform Pre-Dispensed PCR plates Hydrolysis probe technology All-in-one hot start PCR master mix Commercial Impact: Use on installed base of current PCR instruments (ABI Viia7 and Roche LC) in HLA labs Proprietary new Accutyper instrument for labs with no installed instrumentation base Expanded opportunityà migration from Olerup SSP plus market penetration share into larger SSO platform market Revenue from broad and comprehensive kit offerings and instrument sales Status: QTYPE commercially available in H2 2016 QTYPE Available for use on mutliple automated intruments Note: Instruments depicted are Allenex Accutyper, ABI ViiA 7 and Roche Lightcycler 480 Instrument II

Strong Presence in U.S. and Europe ® Direct Sales Distributor Sales San Francisco Stockholm West Chester, PA Vienna Direct Sales Distributor Network

Evolution of Transplant Diagnostics ® Instrument: Sanger Sequencing Reagent: SBT Resolver™ Software: Assign™ Evolving Growth Strategy Long-Standing Partnership with CareDx Global Distribution Rights with Allenex Sequencing Next Generation Sequencing

Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A

CareDx and Allenex at a Glance (USD in MM) CareDx Allenex Combined Market Leadership Leader and innovator post- transplantation surveillance Global leading pre-transplant HLA typing diagnostics Revenue1,2 $28.1 $16.2 $44.3 Net income/loss -$13.7 $0.2 -$13.5 Employees 97 58 155 Footnotes: CareDx actual revenue and net loss for the year ended December 31, 2015 Allenex 2015 actuals translated from 2015 year-end report and converted to US GAAP on an estimated preliminary basis Source: derived from Allenex and CareDx company reports ® 16

Acquisition Deal Terms ® Estimated Acquisition Purchase Consideration     Amounts ($ in millions) % Mix Common Stock Price Per Share         Cash paid   13.6 39%     Commitment to purchase units   8.0 23%     Deferred payment   6.3 18%           79%     Stock distributed   7.2 21% 1,375,029 5.24*     35.1 100%     * Closing stock price on April 14, 2016.

PIPE Financing Drives Growth Initiatives ® Purchase agreements to sell $14.1 million units consisting of the following securities: One share of common stock Five shares of Series A mandatorily convertible preferred stock Purchase price equivalent to $3.99 per share of common stock, assuming preferred conversion Three warrants exercisable initially at $4.98 per share Conversion of preferred and exercisability of warrants pending stockholder approval Commitment agreement to purchase $8 million of units at the same terms Shares shall be subsequently registered

Funding Details ® *Pro forma assumes conversion of mandatorily convertible preferred securities **USD equivalent of debt denominated in Swedish Kroner Securities Purchase Agreement Pro Forma * Common Stock Amounts ($ in millions) Units Analysis Warrants shares Units purchased 14.2 591,860 Common shares in units 591,860 Manditorily convertible preferred shares in units 2,959,300 14.2 3,551,160 1,775,580 Commitment for future securities purchase Commitment to purchase units 8.0 334,169 Common shares in units 334,169 Manditorily convertible preferred shares in units 1,670,845 8.0 2,005,014 1,002,507 Total 22.2 5,556,174 2,778,087 Combined Debt Profile USA - East West Bank 16.0 Sweden - Danske Bank and former shareholders 14.0 ** 30.0

Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A

Key Upcoming Milestones ® 16 Apr 2016 Close of Allenex Acquisition AlloSure Data in Heart at 2016 ISHLT AlloSure Data in Kidney QTYPE Launch May 2016 Jun 2016 H2 2016